NCT00452478 is a Phase 4 clinical trial of Lanthanum carbonate in Kidney Diseases, sponsored by Shire.

Who is sponsoring NCT00452478?

NCT00452478 is sponsored by Shire.

What drugs are being tested in NCT00452478?

Interventions in NCT00452478: Lanthanum carbonate.

What condition does NCT00452478 study?

NCT00452478 studies Kidney Diseases.

Is NCT00452478 still recruiting?

NCT00452478 is currently terminated. Last updated 25 May 2021.

Last reviewed 2021-05-25 · How we verify

NCT00452478

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5

Terminated Phase 4 Last updated 25 May 2021

What this trial tests

Phase 4 trial testing Lanthanum carbonate in Kidney Diseases in 68 participants. Terminated before completion.

Timeline

22 May 2007

Primary endpoint
10 December 2007

10 December 2007

Quick facts

Lead sponsor	Shire
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	68
Start date	22 May 2007
Primary completion	10 December 2007
Estimated completion	10 December 2007
Sites	14 locations across Italy, Denmark, Netherlands, Belgium, Austria, Germany

Drugs / interventions tested

Lanthanum carbonate — full drug profile →

Conditions studied

Kidney Diseases — all drugs for Kidney Diseases →

Sponsor

Shire — full company profile →

Who can join

18 and older, any sex, with Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this research study is to see if giving Fosrenol®, a chewable tablet, to patients on haemodialysis works as well as other treatments currently used to lower blood phosphorus levels.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lanthanum carbonate

Trials testing the same drug.

NCT02209636 — Phosphate Lowering in CKD Trial · Phase 4 · completed
NCT01128179 — Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD · Phase 2 · completed
NCT01130831 — Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy · completed
NCT00557323 — Long-term Effect of Lanthanum Carbonate on Bone · completed
NCT00234702 — Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Ki · Phase 2 · completed

Other recruiting trials for Kidney Diseases

Currently open trials in the same condition.

NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
NCT06759077 — Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life · Phase 3 · active not recruiting

Other Shire trials

Trials by the same sponsor.

NCT05067868 — A Study of Replagal in Children and Adults With Fabry Disease in India · Phase 4 · recruiting
NCT03878953 — A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism · Phase 3 · withdrawn
NCT04840667 — A Study of Replagal in Treatment-naïve Adults With Fabry Disease · Phase 3 · terminated
NCT04429984 — Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India · completed
NCT04440488 — ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study · Phase 4 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00452478 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shire
Last refreshed: 25 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00452478.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing